REGN

Nasdaq

REGENERON PHARMACEUTICALS, INC.

Latest disclosureSeptember 3, 2026

Insider score Why 0?: 0/ 100
Qualifying buys · 30d: $0

0 purchases · 27 sales

Price by TradingView

Insider transactions 39

Limited filing history

Filters

Last 30 daysNo qualifying insider buying. No qualifying insider sales.

Showing the first 6 of 20 trades on this page.

Sale disclosed

Marion McCourt

EVP Commercial

Common Stock

Reported value: $1.03M
Reported price: $850.00 / share

Sale disclosed

Marion McCourt

EVP Commercial

Common Stock

Reported value: $969.71K
Reported price: $857.39 / share

Sale disclosed

Kathryn Guarini

Director

Common Stock

Reported value: $340K
Reported price: $850.00 / share

Sale disclosed

Kathryn Guarini

Director

Common Stock

Reported value: $320K
Reported price: $800.00 / share

Sale disclosed

Huda Y. Zoghbi

Director

Common Stock

Reported value: $640K
Reported price: $800.00 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $130.03K
Reported price: $650.15 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $3.51K
Reported price: $701.76 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $10.54K
Reported price: $702.46 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $16.88K
Reported price: $703.46 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $10.56K
Reported price: $704.28 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $9.88K
Reported price: $705.56 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $4.95K
Reported price: $706.74 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $2.83K
Reported price: $707.40 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $4.26K
Reported price: $709.45 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $1.42K
Reported price: $710.87 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $3.56K
Reported price: $711.49 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $712.09
Reported price: $712.09 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $1.43K
Reported price: $714.13 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $771.32
Reported price: $771.32 / share

Sale disclosed

Arthur F. Ryan

Director

Common Stock

Reported value: $2.32K
Reported price: $772.76 / share

Reporting insider	Security / transaction	Amount / price	Value	Traded / disclosed	Source
EVP Commercial	Common StockSale10b5-1	1,215$850.00 / share	$1.03M	Sep 2Filed Sep 3 · 1d later	SEC filing
EVP Commercial	Common StockSale10b5-1	1,131$857.39 / share	$969.71K	Sep 3Filed Sep 3 · 0d later	SEC filing
Director	Common StockSale10b5-1	400$850.00 / share	$340K	Sep 2Filed Sep 3 · 1d later	SEC filing
Director	Common StockSale10b5-1	400$800.00 / share	$320K	Aug 10Filed Aug 12 · 2d later	SEC filing
Director	Common StockSale10b5-1	800$800.00 / share	$640K	Aug 10Filed Aug 12 · 2d later	SEC filing
Director	Common StockSale10b5-1	200$650.15 / share	$130.03K	Jul 2Filed Jul 7 · 5d later	SEC filing
Director	Common StockSale10b5-112 trades	100avg $705.24 / share	$70.52K	May 1Filed May 4 · 3d later	12 filings 5 @ $701.76 · $3.51KSEC filing 15 @ $702.46 · $10.54KSEC filing 24 @ $703.46 · $16.88KSEC filing 15 @ $704.28 · $10.56KSEC filing 14 @ $705.56 · $9.88KSEC filing 7 @ $706.74 · $4.95KSEC filing 4 @ $707.40 · $2.83KSEC filing 6 @ $709.45 · $4.26KSEC filing 2 @ $710.87 · $1.42KSEC filing 5 @ $711.49 · $3.56KSEC filing 1 @ $712.09 · $712.09SEC filing 2 @ $714.13 · $1.43KSEC filing
Director	Common StockSale10b5-12 trades	4avg $772.40 / share	$3.09K	Apr 1Filed Apr 3 · 2d later	2 filings 1 @ $771.32 · $771.32SEC filing 3 @ $772.76 · $2.32KSEC filing

Showing the latest 20 of 27 trades. Show all 27 trades

Congress transactions 4

All Congress filings

Purchase disclosed

Regeneron Pharmaceuticals, Inc. - Common Stock · Stock

The filing reports a purchase for the member.

AAAlan ArmstrongReporting Senate member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 27, 2026

Sale disclosed

Regeneron Pharmaceuticals, Inc. - Common Stock (REGN) · Stock

The filing reports a sale for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: May 15, 2026

Purchase disclosed

Regeneron Pharmaceuticals, Inc. - Common Stock (REGN) · Stock

The filing reports a purchase for the member.

Julia LetlowReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: February 12, 2026

Purchase disclosed

Regeneron Pharmaceuticals, Inc. - Common Stock (REGN) · Stock

The filing reports a purchase for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: November 18, 2025

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0000872589
Latest public acceptance: Sep 3, 2026, 08:50 PM UTC
Score calculated: Oct 7, 2026, 12:05 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Reporting insider

Security / transaction

Amount / price

Value

Traded / disclosed

Source

EVP Commercial

Common StockSale10b5-1

1,215$850.00 / share

$1.03M

Sep 2Filed Sep 3 · 1d later

SEC filing

EVP Commercial

Common StockSale10b5-1

1,131$857.39 / share

$969.71K

Sep 3Filed Sep 3 · 0d later

SEC filing

Director

Common StockSale10b5-1

400$850.00 / share

$340K

Sep 2Filed Sep 3 · 1d later

SEC filing

Director

Common StockSale10b5-1

400$800.00 / share

$320K

Aug 10Filed Aug 12 · 2d later

SEC filing

Director

Common StockSale10b5-1

800$800.00 / share

$640K

Aug 10Filed Aug 12 · 2d later

SEC filing

Director

Common StockSale10b5-1

200$650.15 / share

$130.03K

Jul 2Filed Jul 7 · 5d later

SEC filing

Director

Common StockSale10b5-112 trades

100avg $705.24 / share

$70.52K

May 1Filed May 4 · 3d later

12 filings

5 @ $701.76 · $3.51KSEC filing
15 @ $702.46 · $10.54KSEC filing
24 @ $703.46 · $16.88KSEC filing
15 @ $704.28 · $10.56KSEC filing
14 @ $705.56 · $9.88KSEC filing
7 @ $706.74 · $4.95KSEC filing
4 @ $707.40 · $2.83KSEC filing
6 @ $709.45 · $4.26KSEC filing
2 @ $710.87 · $1.42KSEC filing
5 @ $711.49 · $3.56KSEC filing
1 @ $712.09 · $712.09SEC filing
2 @ $714.13 · $1.43KSEC filing

Director

Common StockSale10b5-12 trades

4avg $772.40 / share

$3.09K

Apr 1Filed Apr 3 · 2d later

2 filings

1 @ $771.32 · $771.32SEC filing
3 @ $772.76 · $2.32KSEC filing

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0000872589
Latest public acceptance: Sep 3, 2026, 08:50 PM UTC
Score calculated: Oct 7, 2026, 12:05 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.